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1477-8939/ª 2014 Published by ElseviSummary Leishmaniasis clinical spectrum ranges from cryptic infection to fatal visceral
leishmaniasis. Cryptic infection can be found in blood donors from areas endemic for leishman-
iasis all over the world. Although leishmaniasis is a classic vector-borne disease, cases of trans-
fusion transmitted leishmaniasis have been reported especially in nonendemic areas. Most of
these cases regarded infants or children. This paper reviews the literature on this specific
feature and the impact of leishmaniasis on transfusion medicine. Relevant literature was found
through PubMed. The reference lists of selected articles identified further sources. Conclu-
sions: Blood donations by emigrants or travelers from endemic areas require special attention.
Routine diagnostic methods should be implemented in blood banks to exclude donors that are
positive for Leishmania, and individuals who suffered from visceral leishmaniasis should be
prohibited from donating blood. The use of leukodepletion filters at the time of collection
should be recommended in at-risk areas especially for high-risk recipients.
ª 2014 Published by Elsevier Ltd.1. Introduction
Leishmaniasis is a vector-borne disease caused by Leish-
mania species of protozoan parasites. Among 15 well-
recognized Leishmania spp. known to infect humans, 13ie Infettive, AOU Policlinico
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0.
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er Ltd.have a zoonotic nature since canines and rodents are the
principal hosts [1]. The clinical spectrum of the disease
depends largely on parasite species and host immune
response, ranging from asymptomatic infection (80e95% of
affected people) to 3 main clinical syndromes (5e20% of
current leishmaniasis): visceral leishmaniasis (VL), also
known as “kala-azar,” cutaneous leishmaniasis (CL), and
mucosal or mucocutaneous leishmaniasis (ML), also known
as “espundia” [2,3].
The most severe form is VL which affects about
200,000e400,000 people worldwide, causing approximately
618 P. Mansueto et al.20,000e30,000 deaths per year. If untreated it has a mor-
tality rate of almost 100%. India, Nepal, Bangladesh, Sudan
and Brazil account for 90% of all visceral cases, Brazilian
cases represent up to 90% of all cases in the Americas. VL
usually presents with fever, splenomegaly, pancytopenia
and hypergammaglobulinemia [4].
Leishmania (L.) infantum in the Mediterranean basin,
West Africa, and South America (L. infantum chagasi (or L.
infantum MON 1)) is the agent of zoonotic visceral leish-
maniasis (ZVL), and dogs are the only confirmed primary
reservoir of infection [5]. L. donovani causes anthroponotic
VL in the Indian subcontinent and eastern Africa.
In the 90s an increase in cases was noticed mainly due to
the extension of Leishmania-HIV coinfection. It is esti-
mated that in southern Europe between 25% and 70% of
adult VL cases are related to HIV infection [6,7]. The
increased rate of human VL in HIV-infected patients sug-
gests that most cases could be attributable either to a
reactivation of cryptic forms of the disease by HIV immune
system suppression or the inability to avoid primary in-
fections [8].
Although VL is the most severe form of the disease, CL is
by far the most common, 90% of which occurs in
Afghanistan, Iran, Saudi Arabia, Syria, Brazil, and Peru [9].
CL clinical onset is characterized by skin ulcers on the
exposed parts of the body, such as the face, arms and legs,
their number ranging from 1 to as many as 200, causing
serious disability and leaving the patient permanently
scarred. Sometimes the cutaneous form may evolve to a
disseminated form, known as diffuse cutaneous leishmani-
asis (DCL). The main species involved in CL are: L. tropica,
L. aethiopica, L. major, and dermotropic zymodemes of L.
infantum in the “Old World” (i.e. southern Europe, Medi-
terranean basin, Middle East, Asia, and Africa), and para-
sites belonging to the Leishmania Mexicana (L.
amazonensis, L. mexicana, L. venezuelensis) and Leish-
mania Viannia (L. braziliensis, L. guyanensis, L. pan-
amensis, L. peruviana) subgenus complexes in the “New
World” (Latin America). Most of the Old World species
cause benign cutaneous disease, New World species cause a
spectrum of disease, ranging from mild cutaneous disease
to severe mucosal lesions (i.e. ML) [10].
The third form, ML, can lead to extensive and disfiguring
destruction of mucous membranes of the nose, mouth and
throat cavities and can even involve the cartilages. Bolivia,
Brazil and Peru are the most involved Countries, accounting
for about 90% of all cases [11]. As mentioned above just a
small number of New World CL evolves into mucosal forms;
in these cases its course is chronic and may be life-
threatening. Mucocutaneous lesions are quite frequent
complications of the L. Viannia complex infections (more
commonly manifesting in L. braziliensis than in L. guya-
nensis or L. panamensis infections), whereas they are not
typically seen in L. Mexicana complex infections, except
(rarely) when L. amazonensis is involved [12]. All the
Leishmania spp responsible for CL and ML, apart from L.
tropica are zoonotic.
Hematophagous female sand flies (order Diptera, family
Psychodidae, subfamily Phlebotominae) of the Phleboto-
mus genus in the Old World, and of the Lutzomyia genus in
the New World, are the vectors of the disease. Neverthe-
less, fewer than 50 of the approximately 1000 species ofsand flies worldwide are counted as vectors. This could be
due to both the inability of some sand fly species to support
the development of parasite infective stages in their gut,
and to the lack of ecological contact with reservoir hosts
[13]. Female sand flies acquire the infective form of the
parasite (amastigotes) during blood meals, and transmit the
evolved, extracellular, stationary phase, metacyclic pro-
mastigotes, to new hosts through another meal. Promasti-
gotes are then phagocytosed by macrophages and related
cells (monocytes in the blood and in the remainder of the
reticuloendothelial system) in the mammalian host, and
transformed to amastigotes [14]. Possible transmission
routes other than insects have rarely been reported:
placenta, semen, injection needles, organ transplantation,
blood transfusion and laboratory-acquired infections
[15e22].
However, much attention has recently focused on iat-
rogenic and preventable causes of leishmaniasis that
include the transfusion-transmitted route. In infected
human hosts, the overwhelming majority of Leishmania
organisms reside within reticuloendothelial cells and do not
circulate freely in the blood. At the time of blood collec-
tion, organisms are present inside monocytes of infected
donors. Upon storage at 4 C, the organisms remain within
white blood cells (WBCs) for some time, but could even-
tually emerge as free amastigotes that may transform into
promastigotes, able to survive outside the cell in the stored
blood [23].
The evidence of human cases of transfusion transmitted
leishmaniasis (TTL) is of interest, especially VL, with clin-
ical features and outcomes similar to those of the natural
infection, not only in endemic but also in nonendemic areas
[24].
In this paper we reviewed the literature on clinical and
non-clinical features of TTL and its impact on transfusion
medicine. We researched the PubMed database for the
period from 1980 through December 31, 2013, using the
words “leishmaniasis,” “transfusion,” and “blood donor.”
Articles presenting original data on human cases of TTL
were included in our review, as were the review articles.
2. Survival of Leishmania spp. in vitro and in
experimental animals in blood and blood
products
In vitro studies have clearly shown that, under general
blood bank storage conditions, for at least 25 days post-
donation, L. tropica- or L. donovani-contaminated trans-
fusion blood products must be considered at risk. Packed
red blood cells, frozen-deglycerolized red blood cells,
platelet concentrate, and whole blood have been reported
to be involved. In contrast, no reports on fresh frozen
plasma have been published, as would be expected. Intra-
cellular parasites survive longer than stationary phase
extracellular promastigotes or free amastigotes. The par-
asites survive for 25 days as intracellular forms in mono-
cytes in the red blood cell fraction kept at 4 C, for 35 days
in the red blood cell fraction frozen with glycerol, for 5
days in the platelet fraction kept at 24 C, and for 30 days
in unprocessed whole blood left at 4 C. To define the
minimum concentration of L. tropica needed to
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numbers of intramonocytic amastigotes per milliliter of
blood were cultured in whole blood at 4 C; to determine
parasite availability specific aliquots were removed every
day. The study proved that when whole blood was kept
under blood bank conditions, a single L. tropica parasite
survived for 15 days, whereas a 35-day culture inoculum of
at least 256 organisms was required to have viable para-
sites. Animal studies were carried out to assess the pres-
ence of infected monocytes in the blood of cutaneously
infected animals and the possibility of transmitting the
disease by blood transfusion from both infected donor an-
imals and seeded citrate phosphate dextrose-adenine-
1(CPDA-1) bags of human whole blood kept for 30 days at
4 C under blood bank conditions. Viscerotropic L. tropica
was cultured from the blood of 6 of 10 cutaneously infected
hamsters, whereas cutaneous L. major from 5 of 9 cuta-
neously infected BALB/C mice. In 3 of the 5 mice transfused
with a fresh 0.5 mL blood sample from lesion positive BALB/
C donor mice, cutaneous lesions or metastasis to the lower
extremities were observed. In addition, L. major amasti-
gotes were visualized and cultured from the liver and
spleen of 4 of the 5 transfused animals. Similarly, of the 5
mice transfused with blood stored for 30 days at 4 C, 4
developed metastasis to the face and upper extremities,
and amastigotes were evidenced and cultured from the
livers of all 5 transfused animals. In this study by Grogl
et al., 3 additional animals that received 0.25 mL of blood
from a CPDA-1 bag seeded with 10 L. tropica amastigotes
per mL of blood stored for 30 days developed the same
metastasis to the lower extremities or face. Thus it was
clearly proven that Leishmania not only survive under blood
bank conditions, but the parasites retain their infectivity to
healthy experimental animals [23]. TTL has also been
confirmed in dogs [25e27], and in experimental assays with
hamsters and mice, by plasma transfusion as well [28e30].
3. In vivo human findings of Leishmania in
peripheral blood
Leishmania is expected to persist in the blood for an un-
defined period between sand fly inoculation and its final
localization in the target organs. Several in vivo studies
proved that the parasite, after entering the skin through
the blood meal, invades the cells of the reticulo-
endothelial system where it resides and multiplies. Large
mononuclear cells and polymorphonuclear leukocytes are
the location to search for the parasites. The disease usually
starts with an asymptomatic subclinical period, in which
parasites may already be circulating in the peripheral
blood, but the lack of any clinical or hematologic changes
leads physicians to not suspect and diagnose the disease.
These potentially asymptomatic parasite infected blood
donors usually have a very low parasite density (ranging
from 0.001 parasites/mL to 1 parasite/mL), in contrast to
VL patients at diagnosis, who usually have higher titers
(ranging from 8 to 1,400,000 parasites/mL), and may serve
as a source of TTL [2,31,32].
Several studies suggest that the presence of Leishmania
in the peripheral blood of asymptomatic carriers is probably
episodic, suggesting that such individuals are asymptomaticcarriers for a variable period [18,33e60]. The length of this
potentially infective period depends both on the virulence
of the parasite itself (especially zymodeme MON-1) [61],
and on the activity of the cellular immune system of the
subject. Some studies have reported long asymptomatic
incubation periods; furthermore, the parasite can persist in
infected subjects after clinical recovery. In regard to the
infecting species, for L. donovani this period varies from 1
to 14 months [23,62], whereas for other species this period
ranges from 2 to 8 weeks, although some cases have been
reported with more than a one-year incubation period.
Usually asymptomatic infection does not persist for more
than one year, but rarely might persist for decades (up to 30
years) [63]. Furthermore, although lower in impact,
extracellular circulation of L. braziliensis in healed cases of
ML and L. donovani, in patients with asymptomatic in-
fections have been reported [63e65]. Finally, clinical re-
covery of VL is not always accompanied by parasitological
eradication; low parasite titers can be present in the blood
of patients who will not present a relapse [66].
4. Asymptomatic cases of Leishmania infection
and studies on blood donors
Asymptomatic cases of Leishmania infection, especially VL,
including the ones reported in apparently healthy blood
donors, have been reported in India [33,34], Nepal [35],
Bangladesh [36], Iran [37,38], Iraq [60], Turkey [39,40],
Italy [41e43], Greece [44], France [45,46], Spain
[18,47,48], and Brazil [49e51,53e59].
Quite recently, Scarlata et al. evaluated the risk of
transfusion-transmitted VL in an area of south-western
Sicily, Italy (area in which the incidence of symptomatic
VL is higher than the Sicilian average): 1449 blood donors
were screened for anti-Leishmania antibody positivity by
IFAT. PCR to detect Leishmania DNA was used to test blood
samples from IFAT-positive donors. Anti-Leishmania anti-
bodies were found in 11 (0.75%) cases, among which
Leishmania DNA was detected in four [41]. A previous
screening of asymptomatic blood donors from north-
western Sicily, Italy did not detect any positive sample of
L. infantum antibodies by ELISA [42]. These data confirm
that the risk of TTL seems to be variable in different
endemic/non-endemic Sicilian areas [41].
In 1997, Kubar et al. demonstrated Leishmania exposure
by Western blot in 61 of 463 donors in Monaco, Southern
France, with positive blood cultures in 9 of 61 [45]. Some
years later, the same group in Monaco, Southern France,
assessed whether L. infantum circulated in peripheral
blood of blood donors with no history of VL. Sera from 565
subjects were screened by Western blot to detect Leish-
mania-specific antibodies and identify individuals with
probable past exposure to Leishmania. Seropositivity was
found in 76 donors whose BCs were subsequently examined
by PCR and direct culture. The parasite minicircle kineto-
plast DNA was amplified from blood samples of 9 donors.
Promastigotes were detected by culture in blood samples
from 9 donors. Only 2 donors were found to be positive by
PCR and culture [46].
More recently, Kyriakou et al. studied the clinical utility
of flow cytometry for the screening of blood donors in the
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from 2000 blood donors by flow cytometry after labeling
with a polyclonal anti-Leishmania antibody, conjugated
with fluorescein-isothiocyanate, derived from infected ca-
nines in the area. Serum anti-Leishmania antibody search,
May-Gru¨nwald staining of peripheral blood smears, and PCR
in BC to identify the minicircle of kinetoplastic DNA, were
simultaneously performed on the same blood samples. Flow
cytometry detected 33 cases (1.65%), which were all
confirmed by PCR. After pre-storage leukodepletion, no
sample was positive by PCR. Anti-Leishmania antibodies
were positive in 304 (15%) cases. Therefore, flow cytometry
was found to be a sensitive and rapid method to detect
Leishmania in peripheral blood samples, with an efficacy
overlapping PCR. At the same time the study proved that
leucodepletion effectively reduces parasite presence, thus
minimizing the potential risk of Leishmania transmission
through blood transfusions in endemic areas. Unfortunately
flow cytometry is not always available, as it requires
expensive equipment and expertise for the interpretation
of results [44].
In 2004 Riera et al. evaluated the extent of cryptic
leishmaniasis in blood donors from a Spanish endemic area,
(Eivissa, Balearic Islands) using several immunological and
parasitological methods. Sera from 656 blood donors were
examined: 16 (2.4%) were positive by ELISA and 50 (7.6%) by
Western blot. Delayed type hypersensitivity (DTH) tests
were positive in 15/67 donors (22.3%). Peripheral blood
mononuclear cells (PBMC) and BC samples were analyzed by
nested-PCR and culture. DNA of L. infantum was amplified
in PBMC of 27 (22.1%) over the 122 analyzed samples. Par-
asites were isolated in 3 (4.5%) of 67 BC cultures and the
strains were identified as L. infantum zymodeme MON-28
[47].
More recently in 2008 the same authors studied the
prevalence of Leishmania infection in 1437 blood donors
from other Balearic Islands (Majorca, Formentera, and
Minorca). In addition, they used nested PCR in the red blood
cell (RBC) units to test the efficiency of leukoreduction by
filtration to remove the parasite. Anti-Leishmania anti-
bodies were detected in 44 of the 1437 tested blood donors
(3.1%). DTH was performed on 73 of 304 donors randomly
selected from Majorca, 8 (11%) of whom were found posi-
tive. L. infantum DNA was amplified in PBMC in 18 (5.9%),
and cultures were positive in 2 (0.6%). After leukodepletion
all the RBC samples tested (13 of 18) from donors with a
positive PBMC nested PCR yielded negative nested PCR re-
sults. The authors concluded that DTH and L. infantum
nested PCR appear to be more sensitive to detect asymp-
tomatic infection than the serology. The use of leukode-
pletion filters appears to efficiently remove parasites from
RBC units [48].
Franc¸a Ada et al. detected Leishmania asymptomatic
infection in 430 blood donors from the Midwest region of
Brazil. Serum samples were tested by IFAT, and an inter-
view with the blood donors was carried out. Antibodies
were detected in 15.6% of samples. The variables associ-
ated with the infection were: origin of the donor (in this
case, the city of Campo Grande, the main endemic area of
the state), presence of parks or squares (i.e. suitable
environment for the development of vectors of L. infantum
chagasi), presence of dog with clinical signs of leishmaniasis(e.g., skin lesions, limb paresis) in the neighborhood, and
vicinity of leishmaniasis (history of contact with people who
had or died of leishmaniasis), confirming the role of these
patients as reservoirs [57].
Finally, in another VL endemic area in the same state,
Silva et al. evaluated a total of 1241 residents, who un-
derwent anamnesis, clinical examination, and blood
collection for Leishmania serological testing (i.e. ELISA and
IFAT). DHT (Montenegro skin test), was also performed in all
the subjects. In addition, peripheral blood was collected
from a randomly selected portion of this population
(n Z 149) for genus-specific PCR analysis. Forty-nine
(32.9%) of them had a positive PCR result and none of
them developed the disease within a follow-up period
lasting 3 years. No association was observed between the
results of PCR, serological and skin tests. The authors
concluded that a positive PCR result in subjects from the
endemic area does not indicate a risk of progression to VL,
nor is it associated with a positive result in the serological
tests [58].
5. Transfusion transmitted leishmaniasis
In the current international literature, to our knowledge,
there are only a few published cases of TTL, for several
reasons. Among these, one of the most important is related
to the geographical area of transmission; this occurs
prevalently in endemic areas, where the evidence of
transmission by transfusion is extremely difficult to obtain.
Another factor is the silent nature of infection in immune-
competent subjects. Moreover, without a high level of
clinical suspicion, even a symptomatic recipient of an
infected transfusion is likely to be unrecognized as such,
and labeled with a diagnosis of “fever of unknown origin.”
The identification of the TTL cases is also difficult due to
the high number of cases in which infection is present;
even with a high level of suspicion, blood cultures and
spleen aspirates are negative. An additional level of diffi-
culty is caused by the long time the physicians take to
diagnose leishmaniasis from the appearance of symptoms,
which usually ranges from 1 to 16 months. Until recently it
was very likely that most transmission by transfusion
occurred in endemic areas. However, recent changes in
immigration patterns, disease migration, and travel, owing
to environmental changes, have altered the main features
of the disease in nonendemic areas, to which is added an
increase of susceptible, immune-depressed, individuals
(i.e. infants with immature immune systems, HIV-positive
population, patients on steroids for asthma or chronic
obstructive pulmonary disease, patients undergoing
treatment for malignancies, and recipients of organ
transplants). The combination of a predisposed high-risk
population, which often undergoes transfusions, with a
pool of healthy, immune-competent, and therefore,
asymptomatic donors, creates ideal conditions for trans-
mission of the parasite and the onset of the disease. In
addition, more than 95% of L. donovani and L. infantum
infections do not progress to clinically apparent visceral
disease, in spite of the persistence of visceral infection,
demonstrating how likely it would be for Leishmania to be
undetected in an infected donor. Therefore, the number of
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[24,67,68].
Excluding one highly uncertain case report [69], be-
tween 1948 and 2011, we could find only 11 reports of TTL
in the English literature, all from nonendemic areas. Of
these, 10 were individual case reports, whereas the last
one, from Brazil, analyzed 32 cases of kala-azar identified
out of 82 patients undergoing hemodialysis and multiple
transfusions. Of these cases, most regarded infants (neo-
nates) or children. Due to the usually large number of
possible donors the infected ones were identified in only 4
out of the 11 reports on TTL. However, it was not possible
to demonstrate the presence of the parasite circulating
either in the bloodstream of any of the donors or in trans-
fused blood components. All 4 donors were asymptomatic
at the time of blood donation [24,70e72].
In 1948 Chung et al. reported the first transfusion-
transmitted kala-azar cases in China. The blood was
donated from an infected mother to 2 daughters, aged four
and six years old. The mother’s blood (20 mL) had been
given by intramuscular injection as a prophylaxis for mea-
sles prevention. A few days later the mother was admitted
to a local hospital for fever, paleness, and distension of the
abdomen and was diagnosed with kala-azar one month
later. Both daughters were closely observed and developed
kala-azar nine and ten months after receiving the trans-
fusion [71]. Other reports of transfusion-transmitted kala-
azar following these 2 case reports were reported from
France, Sweden, Belgium, United Kingdom, Greece, India,
Colombia and Brazil [24,49,70,72e77]. In September 1955 a
44-year-old French man donated his blood to 2 newborn
infants after he had traveled to Spain. A few weeks later he
developed skin rash and lymph-adenopathy. The scraping
from the skin nodules showed amastigotes. The 2 infants
developed anemia after 10 months, which progressed to
kala-azar. Bone marrow analysis of one child was found
positive for L. infantum. The other infant died within three
months [72]. Another two cases of transfusion-transmitted
kala-azar have been reported in Sweden. Blood from a
healthy asymptomatic donor who had recently traveled
outside that country was transfused to 2 newborns. In the
following six months both recipients fell ill. One of them did
not survive and an autopsy revealed kala-azar. Based on the
pathological diagnosis of Kala-azar, the second new born
was treated and survived [77].
In 1991 the first case of TTL was reported in Belgium in
an 11-month-old infant who had never left his native
country. Shortly after birth, the child was repeatedly
transfused for anemia. The period of incubation was 9
months [73]. A post-operative and post-transfusion case of
VL, also affecting a child, was reported in United Kingdom
in 1995. Neither the child nor his mother had ever been out
of the UK [74].
While all the above reported cases describe VL in in-
fants, Mpaka et al. reported the case of a 77-year-old Greek
woman with renal failure on hemodialysis, admitted to an
intensive care unit (ICU) with vascular instability requiring
vasopressor treatment. Bone marrow analysis demon-
strated multiple intra-cellular Leishmania amastigotes.
After liposomal amphotericin B was administered, the pa-
tient experienced a quick clinical response. Unfortunately,
ten days after admission, the patient died fromuncontrolled septic shock from a secondary bacterial
infection. Non-vector transmission could be suspected in
this case, since the patient had undergone cholecystectomy
three months earlier, during which two blood units had
been transfused. A subsequent serological analysis of the
two donors found they were positive for IgG anti-
Leishmania antibodies, at a high titer in one of them. A
probable large parasite load from the blood transfusion
during cholecystectomy, in an old debilitated patient, was
probably the cause of the rather rapid presentation of the
infection, and the unexpected deterioration to cardiovas-
cular instability needing vasopressor therapy, in the clinical
form of septic shock [70].
In India Singh et al. reported the first two cases of
probable transfusion-transmitted kala-azar. The first pa-
tient was a 6-year-old boy from Uttar Pradesh, Northern
India, a nonendemic area. He was on maintenance therapy
for acute lymphoblastic leukemia and had received several
blood transfusions. The second patient was a 30-year-old
woman from Haryana near Delhi, another nonendemic
area. After the delivery of her fifth child she suffered from
recurrent hemorrhoid bleeding, causing a severe anemia,
which required transfusions on two occasions. Both patients
had never visited any area endemic for L. donovani [75].
Dey et al. reported another Indian case of a transfusion-
transmitted fatal kala-azar in a child who acquired this
infection within a few days of his birth after receiving blood
from his maternal uncle. The man, who was asymptomatic
at the time of blood donation, died within three months
due to severe kala-azar. At the onset the baby developed
fever and hepatosplenomegaly within one month of blood
transfusion and, in spite of repeated anti-leishmanial
treatment with sodium antimony gluconate, the child
died at the age of 7 months. The mother’s seronegative
status for leishmaniasis ruled-out the possible congenital
transmission of the disease. Moreover, because no other
family member suffered from kala-azar at the time of
illness, the possibility of vector borne acquisition of this
parasite was excluded [24]. More recently in 2011, Mestra
et al. reported a case of transfusion-transmitted fatal VL,
caused by L. (L.) mexicana, in a 42-year-old male resident
of northwestern Colombia. After developing terminal renal
failure due to lupus nephritis, he underwent immunosup-
pressive therapy to treat the lupus and prevent transplant
rejection. He received a renal transplant but to maintain
good hemodynamic status he was forced to receive multiple
transfusions, for a long time and from many different do-
nors. Multiple intracellular Leishmania amastigotes were
demonstrated in both renal biopsy and marrow aspirates.
Cultures of the parasite were obtained in NNN medium and
the identification of the species was done both by direct
immune-fluorescence and PCR-restriction fragment length
polymorphism. This data must be considered in function of
the specific epidemiology of leishmaniasis in Colombia; it is
the country with the highest number of Leishmania species
as causative agents of the disease in different clinical
forms. Of all the cases annually reported, 99.3% correspond
to CL and 0.4% to ML, whereas VL accounts only for 0.3%. L.
(L.) infantum is responsible for the 0.3%. However, the VL
case reported here was caused by L. (L.) mexicana, a
species of Leishmania that has been associated exclusively
with CL. Most likely the immunosuppressive therapy
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tion of L. (L.) mexicana. In this case, when blood was
transfused to an immune-suppressed patient, Leishmania
parasite behaved as an opportunistic infection and invaded
organs of the mononuclear-phagocyte system, causing
clinical manifestations compatible with VL [76]. Finally, Luz
et al. investigated the prevalence of anti-L. donovani an-
tibodies in 1500 Brazilian blood donors and multiply trans-
fused hemodialysis patients [49]. The fucose-mannose
ligand (FML) ELISA, which was shown to have 100% sensi-
tivity and 96% specificity for kala-azar, was used to test the
sera (81). Among 1194 volunteer blood donors, seror-
eactivity (positive to ELISA) was found in 9%, increasing to
25% in a periurban kala-azar focus. However, higher posi-
tivity (37%) was found in multiply transfused hemodialysis
patients from Natal, where kala-azar could be considered
endemic (a few cases are frequently reported), with spo-
radic outbreaks in localized regions (endemic and
epidemic). Risk factors included blood transfusion (in this
sample there were 32 multiply transfused hemodialysis
patients), which was significantly associated with the
presence of anti-Leishmania antibodies, but did not include
potential exposure to sand fly bites. Significantly, the
prevalence decreased to 7% in hemodialysis patients from
Rio de Janeiro, where kala-azar is just an occasional
occurrence, and strikes 0% of patients undergoing contin-
uous ambulatory peritoneal dialysis. The prospective anal-
ysis of 27 FML-seroreactive donors from Natal revealed
amastigotes of Leishmania in the bone marrow of one
subject, while 4 had clinical complaints, including hep-
atosplenomegaly [49,78].
Unlike the previously described cases, a probable
platelet transfusion-transmitted kala-azar was highlighted
in a child from India, suffering from idiopathic thrombo-
cytopenic purpura, treated with steroids, immunoglobulin
and repeated platelet transfusions (6 times) over a period
of 2e3 years [79]. Leishmania can easily survive and be
infective in the platelet fraction of blood, up to 5 days at
24 C, the recommended storage period for platelet
transfusion. In the same study, Grogl et al., proved that the
number of mononuclear cells, which can usually be found in
red blood cell or platelet packs, is sufficient to contaminate
these blood products with viable Leishmania. However,
platelet transfusion-acquired leishmaniasis had not been
reported until this case [23].
6. Screening of blood donors
Therefore, considering the potential risk of Leishmania
transmission through blood transfusion, the need for con-
trol of blood products is clearly recognized. This recom-
mendation is primarily related to demographic changes and
to increases in international travel and human migration
from endemic areas. As an example, in India migration of
residents from kala-azar endemic states (i.e. Bihar, West
Bengal, and Assam) to Delhi and other Western parts of
India for jobs has become a major issue. Among these mi-
grants the high unemployment rates force apparently
healthy subjects to sell their blood. The risk of transfusion-
transmitted kala-azar may be worsened by the short supply
of blood in Delhi. The huge gap between demand andsupply of the blood, leads to storage at 4 C for a period of
35 days, which is required to kill this parasite under blood
banking conditions, in only a small number of units [23].
Although in India most of the professional blood donors
are tested for HIV, hepatitis B and C, there are several
other infectious agents not routinely screened for,
including L. donovani. Furthermore, although government
blood banks do not accept blood from professional donors,
the private ones do, and in most instances the source of
blood is kept secret, because proof of infected donors
might jeopardize a thriving blood business. In the USA,
although no case of TTL has been reported, the Desert
Storm operation raised important concerns about the pos-
sibility of TTL [23]. Therefore, on November 12, 1991, the
Department of Defense issued a statement of a newly
recognized form of viscerotropic leishmaniasis due to L.
tropica among military personnel. Consequently the
American Association of Blood Banks (AABB) recommended
that individuals who had traveled to or visited Saudi Arabia,
Kuwait, Iraq, Oman, Yemen, Qatar, Bahrain or the United
Arab Emirates, on or after August 1, 1990, should be de-
ferred as donors of transfusion blood components until
January 1, 1993 (for about 12 months), with permanent
deferral of subjects with apparent skin infection. This last
deferral did not extend to US soldiers in Afghanistan since
they had already been deferred because of malaria [80].
Afterwards, AABB suggested applying a blanket policy to
better prevent TTL by not drawing blood from individuals
who are at potential risk of being infected with the parasite
[81]. The US Food and Drug Administration agreed with such
a deferral policy as a measure to ensure the safety of the
nation’s blood supply from transmission of Leishmania [82].
Similarly, in 2009 the Pan American Health Organization
recommended permanently refusing blood donations from
individuals who have had leishmaniasis, and does not allow
donations for a period of at least two years from asymp-
tomatic carriers or subjects with a history of travel or
transfusion at risk of being infected [83].The International
Forum showed that in most European countries no specific
measures are implemented to prevent TTL, since in none of
the countries that participated in this International Forum,
was TTL observed over the last 10 years. Only Ireland defers
donors for 12 months if they have visited Iraq [84]. Finally,
there is a concern by the World Health Organization (WHO)
to certify the safety of blood, and to make progress in
relation to donor recruitment and blood collection, as well
as in the routine testing on the samples of these donors
[85].
Nevertheless, in the light of published data a reconsid-
eration of transfusion policy seems to be necessary, as the
impact on the blood supply is expected to be significant,
although, to date, it is difficult to estimate the exact
number of donors who will be deferred. Therefore, in this
delicate context adequate blood donor screening must be
considered the first step.
Diagnosis of leishmaniasis depends both on the clinical
symptoms of the infection, and on the antileishmanial
antibody titers or detection of the parasite in samples ob-
tained from patients. However, both the low antibody titers
and the low number of parasites in samples of individuals
with asymptomatic leishmaniasis, make the sensitivity of
the actual diagnostic tools insufficient. Immunodiagnostic
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as rK-39, developed from L. chagasi of the New World, or a
recently developed recombinant antigen rKE16, from Indian
L. donovani, can be used for mass screening of donor blood
samples. Gel diffusion, indirect hemagglutination assay,
direct agglutination test, immunochromatographic test,
complement fixation, counter-current immune-electro-
phoresis, indirect fluorescent antibody test (IFAT), and
Western Blot represent some other possible serological
methods to determine specific Leishmania antibodies in
serum samples. However, especially in endemic regions, a
positive test for antibodies against Leishmania does not
necessarily indicate active infection, but it may just be the
result of a previous exposure. In addition, antibodies to
Leishmania are not a reliable indicator of donor prevalence
or infectivity. They can always be detected in patients with
symptomatic visceral infection, whereas they are usually
undetectable in patients with asymptomatic viscerotropic
infection, and moreover usually become negative after
treatment of visceral disease. Therefore, they must be
considered a good marker for active visceral disease, but a
poor one for asymptomatic infection. Finally, but not less
important, these methodologies may have technical and
financial limits [52,54,56,86e89].
Parasitological techniques (i.e. direct examination and/
or culture of bone marrow, lymph nodes, liver or spleen)
remain the “gold standard” tools to confirm active Leish-
mania infection. Nevertheless, in epidemiological research
these methods are inappropriate, because of both the na-
ture of the samples and the invasive nature of the sampling
procedures [86].
In recent years other less aggressive diagnostic tools
oriented to detect the parasites have been considered.
Several studies have shown that PCR is a useful alternative
to traditional methods both for diagnosis and follow-up of
leishmaniasis patients (especially those suffering from VL)
and to detect parasitemia in asymptomatic carriers. One of
the advantages of PCR is that it can be performed on any
biological sample (skin tissue, bone marrow and blood),
with high sensitivity [18,32,86,90e95].
In addition, previous studies proved that in endemic
areas even if no detectable humoral immune-response can
be found, Leishmania DNA might be present in blood from
healthy people [32,47,50,51]. This last evidence, charac-
terizing asymptomatic infection, has also been observed in
dogs with cryptic L. infantum infection. It has been
concluded that antibody-based testing does not clearly
differentiate between non-infected and infected asymp-
tomatic dogs, and that culture and PCR are more reliable
diagnostic tools [96e100].
Riera et al. clearly evidenced the underestimation of
ELISA in determining prevalence of Leishmania infection in
blood donors. They proved that in an endemic area of Spain
ELISA had a prevalence of just 2.4%, Western blot 7.6%, and
finally nested PCR 22% [47]. Furthermore, even a well
known and proven technique as cultures has shown low
sensitivity values compared to PCR, in asymptomatic car-
riers. This may be due to the low level of circulating par-
asites in these latter individuals, which is sufficient for PCR
positivity but not to provide a positive culture [47,48]. This
high sensitivity value of nested PCR compared to the lower
sensitivity of specific antibody detection techniques, andthe rapid clearance of parasite (or dead parasite) DNA,
indicate that nested PCR should be used to detect current
infections in asymptomatic [32,47,86,90e95,101].
In this context, with the increased concern for blood
safety due to emerging pathogens and the threat of bio-
terror agents, which might be transmissible through blood,
the need for rapid pathogen detection becomes even more
important. However, the cost and logistical burden of
testing for many phylogenetically diverse pathogens call for
a multiplex assay. Selvapandiyan et al. developed a multi-
plex polymerase chain reaction assay able to simulta-
neously identify the presence of both bacterial (B.
anthracis and Y. pestis) and parasitic (Trypanosomatid
species, including Leishmania) pathogens in blood speci-
mens. To obtain higher sensitivity of the assay, the re-
searchers chose to specifically amplify genes that can be
found in multiple copies in the microorganisms [102].
Finally, and in contrast to the above-mentioned consider-
ation on PCR efficacy, other authors argue that little
experience with Leishmania primers may lead to false-
positive results, which can be a real concern [103]. How-
ever, some physicians believe that universal screening for
anti-leishmanial antibodies, discarding the blood of Leish-
mania-positive donors, would decrease the blood supply.
Currently this remains a debatable issue. Further studies
appropriately designed to analyze the prevalence and cost-
benefit ratio of anti-leishmanial antibody screening are
needed to determine whether screening needs to become a
routine procedure in blood banks [86].
7. Prevention
TTL requires parasites to be present in the blood either
(and especially) within infected monocytes or (less prob-
ably) as free amastigotes released from mononuclear
phagocytes. Obviously, the parasites must survive blood
processing and storage [23,104]. Recently, using in vitro
experiments several methods designed to inactivate
Leishmania in blood products have been tested. These
include the use of riboflavin (as a photosensitizer) and ul-
traviolet light [105], and the photochemical treatment by
amotosalen plus ultraviolet light in platelet concentrates
[106,107] as well as by thiopyrylium in RBC suspensions
[108].
In the first method, riboflavin can rapidly traverse lipid
membranes of the parasite and non-specifically in-
tercalates with nucleic acids. Upon light exposure, the
riboflavin causes modification of the pathogen nucleic acid
through the oxidation of guanine residues and generation of
reactive oxygen species. As a result of these photochemical
processes, pathogens in blood products are rendered un-
able to replicate due to nucleic acid modification. This
technology exploits the absence of nucleic acids in all the
blood components (including plasma and platelet concen-
trates), which are beneficial to transfusion, and that
instead is present in the parasite [105,109].
In the second method, amotosalen, a synthetic psoralen
compound, reversibly intercalates into the helical regions
of DNA and RNA. Under UVA light at 320 nme400 nm
exposure, amotosalen forms covalent monoadducts with
pyrimidine bases on a single strand of nucleic acid. Further
624 P. Mansueto et al.exposure to UVA light causes the monoadduct to link with a
second pyrimidine base, producing an inter- or intrastrand
cross-link, therefore disabling the transcription and repli-
cation processes. The cross-linked genomes of pathogens
can no longer function or replicate. The system has been
successfully used to inactivate a broad spectrum of viruses,
bacteria, and parasites (such as Leishmania), in platelet
components, not affecting their function and/or structural
features. However, this technology is not effective for red
blood cells or whole blood, because the UV light does not
manage to penetrate sufficiently to activate the amotosa-
len, and induce nucleic acid cross-linking [106,107].
The third method uses thiopyrylium, a flexible photo-
sensitizer, which intercalates into the helical regions of
DNA. Upon 1$1 J cm2 red light, thiopyrylium creates bonds
with nucleic acid bases. This cross-linking makes the
genome of pathogens no longer functional or able to
replicate. The system has been successfully used to inac-
tivate Leishmania in red cell suspensions [108].
The benefits of leukodepletion of blood products to
remove several pathogens (e.g. cytomegalovirus, human T-
lymphotropic virus, the rickettsial species Orientia tsutsu-
gamushi, and Trypanosoma cruzi) from blood components
have been tested, and have led to the increased use of this
technique. Leukodepletion filters of different types have
been designed to be used at the time of collection or at the
time of transfusion. Because Leishmania protozoans are
intracellular monocyte pathogens, it seemed theoretically
possible to use leukodepletion filters as a means to remove
the organisms from infected blood products. Nowadays, the
use of leukodepletion filters, especially at collection time,
when the organism is predominantly intracellular, or with
bedside filters after storage, seems to be the most efficient
means to reduce Leishmania transmission hazard. This
processing can be particularly useful in at-risk areas and for
high-risk (immune-suppressed) recipients, thus improving
quality and safety in the collection and transfusion of
blood. Nevertheless, due to high costs (about V50 per blood
unit) this procedure is used only in selected cases. In this
context, the use of this and other blood protection pro-
cedures would be considered mandatory in the case of re-
cipients with co-infections and/or immune-suppression,
which appear as aggravating factors triggering greater
morbidity. In addition, to complete this complex decision,
the high cost of hospitalization for patients with VL cannot
be ignored, coupled with the low availability of beds in
public hospitals, and the toxicity of drugs used in the
treatment [44,48,110].
Use of whole-blood filters at collection causes a 3- to 4-
log reduction of WBCs (99.31% <1  106 leucocytes). At this
time, considering that all the parasites should be contained
within monocytes, there is a direct correlation between the
ability of the filter to remove leukocytes and parasite
depletion. However, the possible presence of free amasti-
gotes, due to WBC breakdown during filtration, which could
survive outside the cells in blood stored at 4 C, may in-
crease the risk of transmission [23,30,110,111].
Mechanical trapping and charge-related interactions be-
tween cells (i.e. promastigotes and extracellular amasti-
gotes) and filter fibers, as well as interactions of cells with
WBCs also trapped within the filters, have been shown to be
other effective mechanisms to remove promastigotes andextracellular amastigotes, besides the removal of WBCs. For
this reason it may be useful to also use bedside filters after
storage. Nevertheless, although the leukodepletion system
leads to a reduction in parasite detection, the existence of
different filtration systems makes further research necessary
to determine the efficacy of leukodepletion, with particular
regard to other blood components, as well as to determine
the usefulness of other methods to remove or inactivate the
parasite in blood. In any case, the relatively low number of
recently reported cases of TTL in nonendemic areas of
Europe might be explained by the widespread use of leuko-
depletion filters in these regions [110,112].
8. Conclusion
The transmission of Leishmania spp through transfusion is a
relatively rare although probably underestimated event.
Routine diagnostic methods should be implemented in
blood banks to exclude donors that are positive for Leish-
mania. Individuals who suffered from visceral leishmaniasis
should be excluded from donating blood. The use of leu-
kodepletion filters at the time of collection should be rec-
ommended in at-risk areas especially for high-risk
recipients.
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